Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 7,884 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Carbohydrates Clear all
Completed Phase 2 Interventional Results available

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

NCT03019640
View directory record Official record
Conditions
Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Indolent Adult Non-Hodgkin Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Cytarabine, Etoposide, Filgrastim, Lenalidomide, Melphalan, Rituximab
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 20, 2026, 6:11 PM EDT
Completed Phase 3 Interventional

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

NCT06065540
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
2,734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
100
States / cities
Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 20, 2026, 6:11 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Sodium Stibogluconate as a Treatment for Leishmaniasis

NCT00657618
View directory record Official record
Conditions
Leishmaniasis
Interventions
Sodium Stibogluconate (SSG)
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
Not listed
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 20, 2026, 6:11 PM EDT
Terminated Phase 3 Interventional

Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure

NCT01111682
View directory record Official record
Conditions
Traumatic Brain Injury, Elevated Intracranial Pressure
Interventions
Mannitol, Hypertonic Saline
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 20, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

NCT02504359
View directory record Official record
Conditions
Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Ixazomib Citrate, Melphalan, Methotrexate, Peripheral Blood Stem Cell Transplantation, Quality-of-Life Assessment, Tacrolimus
Procedure · Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Durham, North Carolina • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 20, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

NCT01939496
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
54
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 20, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking

NCT02995915
View directory record Official record
Conditions
Smoking Cessation, Alcohol Drinking
Interventions
Nicotine Replacement Therapy, Bupropion, Cognitive Behavioral Treatment, Mobile Contingency Management, Mobile Monitoring
Other · Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 20, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

NCT00866918
View directory record Official record
Conditions
Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm
Interventions
Arsenic Trioxide, Cytarabine, Diagnostic Laboratory Biomarker Analysis, Idarubicin, Mercaptopurine, Methotrexate, Mitoxantrone Hydrochloride, Tretinoin
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 21 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
112
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 87 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 20, 2026, 6:11 PM EDT
Terminated Phase 1 Interventional

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma

NCT00003060
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
filgrastim, busulfan, cyclophosphamide, cyclosporine, methotrexate, allogeneic bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
16 Years to 44 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 20, 2026, 6:11 PM EDT
Completed Not applicable Interventional Results available

Hyperglycemia in Renal Transplantation

NCT01643382
View directory record Official record
Conditions
Diabetes, End Stage Renal Disease
Interventions
Insulin, Insulin, Asp(B28)-
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 20, 2026, 6:11 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568
View directory record Official record
Conditions
Endometrial Cancer
Interventions
BNT323/DB-1303, Doxorubicin, Paclitaxel, Docetaxel
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 6:11 PM EDT
Terminated Phase 2 Interventional Results available

Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

NCT01220297
View directory record Official record
Conditions
Hematologic Diseases, Acute-graft-versus-host Disease, Leukemia, Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma
Interventions
Sirolimus, Mycophenolate mofetil (MMF), Carmustine, Etoposide, Cyclophosphamide (Cyclo, CY), FTBI
Drug
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 60 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 20, 2026, 6:11 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effects of Resveratrol Supplementation on Measurements of Health and Human Performance

NCT01244360
View directory record Official record
Conditions
Inflammation
Interventions
resveratrol, Placebo Comparator: Sugar Pill
Dietary Supplement · Other
Lead sponsor
Marywood University
Other
Eligibility
45 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2011 · Synced Oct 20, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Endogenous Opioid Activity and Affective State in Insulin Resistant Women

NCT02069379
View directory record Official record
Conditions
Depression, Insulin Resistance, Metabolic Syndrome
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 20, 2026, 6:11 PM EDT
Recruiting Phase 1 Interventional

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02390635
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Promyelocytic Leukemia With PML-RARA
Interventions
Computed Tomography, Diffusion Weighted Imaging, Fludeoxyglucose F-18, Gadolinium, Magnetic Resonance Imaging, Positron Emission Tomography, Three-Dimensional Spoiled Gradient MRI
Procedure · Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 6:11 PM EDT
Terminated Phase 1 Interventional

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors

NCT01081808
View directory record Official record
Conditions
Neoplasms, Tumors, Solid Tumors, Metastatic Cancer
Interventions
EGFRBi-armed autologous activated T cells
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 20, 2026, 6:11 PM EDT
Not listed Phase 2 Interventional

Statins and Breast Cancer Biomarkers

NCT00914017
View directory record Official record
Conditions
Breast Cancer
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
35 Years to 55 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
7
States / cities
San Francisco, California • Newark, Delaware • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2010 · Synced Oct 20, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis

NCT04118010
View directory record Official record
Conditions
Cystic Fibrosis, Dysbiosis
Interventions
Vitamin D3, Placebo vitamin D3, Inulin, Placebo Inulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 20, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions

NCT01981759
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Delusional Disorder
Interventions
D-Cycloserine, Placebo, Cognitive Behavioral Therapy
Drug · Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 68 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 20, 2026, 6:11 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

NCT05142696
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
[177Lu]Lu-DOTA-TATE, Atezolizumab, [68Ga]Ga-DOTA-TATE, Carboplatin, Etoposide
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Orlando, Florida • Athens, Georgia • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 20, 2026, 6:11 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00033696
View directory record Official record
Conditions
Lung Cancer
Interventions
filgrastim, carboplatin, etoposide, paclitaxel, topotecan hydrochloride, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
51
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 20, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study

NCT01865162
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
ketogenic diet
Other
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 20, 2026, 6:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Monitoring Postprandial Blood Glucose and Insulin in Fruit Snacks

NCT06458946
View directory record Official record
Conditions
Blood Glucose, Blood Insulin
Interventions
Fruit snack 1, Fruit snack 2, Fruit snack 3, Fruit snack 4, Fruit snack 5, Confection control
Dietary Supplement
Lead sponsor
Ocean Spray Cranberries, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 20, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT03382561
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Etoposide, Nivolumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
779
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Anaheim, California + 518 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 20, 2026, 6:11 PM EDT